Macrocyclics News and Resources

Ratio Therapeutics Inc. has entered into an exclusive agreement with Macrocyclics Inc., granting the CDMO the global manufacturing and distribution rights to its proprietary Actinium-225 chelator, Macropa™. The deal aims to expand worldwide access to the bifunctional chelator, enabling researchers across industry